Quince Therapeutics Inc. has announced that it has engaged LifeSci Capital as its exclusive financial advisor to assist with its restructuring and the evaluation of strategic alternatives aimed at maximizing shareholder value. Potential options under consideration include partnerships, joint ventures, mergers, acquisitions, licensing, or other strategic transactions. LifeSci Capital will also advise the company on any restructuring of its liabilities. Quince stated that it does not intend to provide further updates unless a specific course of action is approved by its Board of Directors or further disclosure is deemed appropriate.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260209949613) on February 09, 2026, and is solely responsible for the information contained therein.